Strategic partnerships Form targeted outreach to Daiichi Sankyo, Oracle, and AMD leveraging 4D Path’s predictive oncology platform to co-develop next-generation biomarkers and scale computational oncology capabilities for ADC programs and broader clinical use.

Clinical to commercial Highlight the Q-Plasia OncoReader as a differentiator for precision therapy selection from routine biopsy images, pursuing contracts with cancer centers and payers seeking faster, more accurate treatment decisions to improve outcomes and reduce costs.

Funding leverage Position 4D Path as a growth partner with recent strategic financing and board additions to attract investors and large biopharma alongside potential grant funding for expansion into additional tumor types and real-world evidence studies.

Scale and enablement Offer enterprise-grade deployment via cloud and AI infrastructure collaborations (Azure, CloudFlare, Sucuri) to accelerate onboarding for mid to large biopharma, CROs, and hospital systems needing scalable predictive analytics for oncology programs.

Market expansion Target mid-sized biotechs and diagnostics firms in oncology where the platform’s rapid, image-based biomarker prediction can shorten development timelines, enabling faster progression to trials and companion diagnostic strategies.